Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including RNA design and custom assay development, for biopharma and biotech companies and as a la carte services. Our areas of support include: • RNA therapeutic sequence design informed by biological data through our eNAVIGATE platform • The optimization and characterization of RNA-based vaccines and therapeutics through our eMERGE platform • Multiomic characterization of small molecule and small oligonucleotide targets • Robust validation of on-target, and the identification of off-target, effects from small molecule and small oligonucleotide drugs • Deep profiling of RNA for groundbreaking discoveries in academic research Contact us today to discover how we can provide you with the insights needed for RNA success.
Looking for a particular Eclipsebio employee's phone or email?
The Eclipsebio annual revenue was $8.9 million in 2026.
Peter Chu is the Co-Founder, CEO and Chairman of Eclipsebio.
32 people are employed at Eclipsebio.
Eclipsebio is based in San Diego, California.
The NAICS codes for Eclipsebio are [541, 54, 5417, 541713, 54171].
The SIC codes for Eclipsebio are [87, 873].